Transcription of ANNUAL REPORT 2017 - viforpharma.com
{{id}} {{{paragraph}}}
ANNUAL . REPORT . 2017 . ANNUAL REPORT 2017 . AT A GLANCE. Guidance raised at half-year, continued good performance in H2. led to strong full-year results Net sales CHF 1, million, up on a constant currency basis EBITDA CHF million, up excluding Veltassa launch costs Cash net of debt of CHF million Transformation into a pure-play pharmaceutical company successfully completed Separation of Galenica Sant via initial public offering (IPO). Etienne Jornod re-elected as Executive Chairman with remuneration exclusively in shares blocked until 2020. Change of name from Galenica Group to Vifor Pharma Group New Executive Committee appointed Operational headquarters transferred from Bern to Zurich Reported net sales growth of Ferinject + for full year 2017 .
Vifor Pharma Ltd. Annual Report 2017 ExECUTiVE MESSAGE 4 172 ExECUTiVE CHAiRMAN Dear Shareholder, It is with great pleasure that I deliver my message as Executive Chairman for the first …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
SEPTEMBER 2017 ENGLISH FIRST, GRADE 12 SEPTEMBER 2017 MATHEMATICS P1, AP English Literature and Composition Syllabus, 2017, Speech 2017-18 Bismillahir-Rehmanir-Rahim PART, First Issuance of Foreign Currency Denominated, First Issuance of Foreign Currency Denominated Green Bonds, Montgomery County Public, Montgomery County Public Schools 2017, Preparing for an Apprenticeship